This on-demand webcast is available with synchronized slides and video/audio.

To be eligible for credit, participants must complete the educational activity, complete the 4-question post-test with a minimum score of 70%, and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: January 20, 2023.
Expiration Date: January 20, 2024. 
Estimated Time to Complete: 1.00 hour

There is no fee associated with this activity.

After participating in this activity, learners should be better able to:

• Assess guideline recommendations, testing techniques, and clinical applications for molecular profiling to identify patients who will benefit from ALK, ROS1, or NTRK-targeted therapy
• Evaluate clinical efficacy and safety data for new and emerging ALK, ROS1, and NTRK-targeted agents against treatment resistance and CNS metastases
• Utilize adverse event management strategies to optimize treatment efficacy and mitigate treatment risks